

Date and Time: 8th May 2012, 10:30-16:30

Minutes: Confirmed

Hepatitis B GDG Meeting 7

Place: NCGC Boardroom, 180 Great Portland Street, London, W1W 5QZ

Present: GDG

1. Howard Thomas (Chair)	HT
2. Elizabeth Boxall	EB
3. Javier Vilar	JV
4. Geoffrey Dusheiko	GD
5. Gareth Tudor-Williams	GTW
6. Emily Lam	EL
7. Sarah Wise	SW
8. Patrick Kennedy	PK

NCGC Technical team

9. Gill Ritchie	GR
10. Grammati Sarri	GS
11. Rosa Lau	RL
12. Sarah Birmingham	SB
13. Amy Kelsey	AK
14. Grant Hill-Cawthorne	GHC

NICE

15. Sarah Dunsdon	SD
-------------------	----

Apologies

16. Angela Narbey	AN
17. Alan Mitchell	AM
18. Aftab Ala	AA
19. Joyeta Das	JD

Notes

1. The Chair welcomed everyone to the Hepatitis B Guideline Development Group (GDG) meeting 7. Apologies were received from Angela Narbey, Alan Mitchell, Aftab Ala and Joyeta Das. The Chair welcomed Patrick Kennedy as a full GDG member to the group. Patrick is a Consultant Hepatologist and senior lecturer at the Royal London Hospital.
2. The Chair asked the GDG to declare if they had any personal specific, personal non-specific, non-personal specific or non-personal non-specific interests to declare since their previous declaration (upon acceptance of their GDG role). The following declarations of interest were made:

EB and SW declared the same non-personal pecuniary interest; they have been asked to sit on an advisory group for Sanofi Pasteur MSD on best practice for delivery of Hepatitis B vaccine to babies at risk in June 2012.

PK declared a non-personal pecuniary interest; he received an educational grant from Gilead Sciences, Roche and BMS all supporting the set up and delivery of the young adult clinic at Barts and the Royal London Hospital. The grant was to aid the initial set up followed by support for the experimental work looking at the drivers of immune mediated damage in young patients (2010 – 2011).

GTW declared a non-personal pecuniary interest; he took part in a scientific advisory group for the European Medicines Agency on 3rd May 2012 that discussed tenofovir use in children with HIV infection and HBV infection.

3. The Chair then briefed the group on the meetings objectives.
4. The Chair introduced Grammati Sarri, NCGC Senior Research Fellow who gave a presentation on results of the Network Meta Analysis for HBeAg positive patients. The Chair thanked GS for her presentation.
5. The Chair then introduced Rosa Lau, NCGC Research Fellow, who gave a presentation on the most appropriate healthcare setting to initiate pre-therapeutic tests in people who are HBsAg positive. The GDG then discussed the evidence presented and drafted recommendations. The Chair thanked RL for her presentation.
6. RL then gave a presentation discussing the thresholds for referral to specialist services after initial diagnosis and pre-therapeutic tests of chronic hepatitis B. The GDG then discussed the evidence presented and drafted recommendations. The Chair thanked RL for her presentation.
7. The Chair then introduced Sarah Bermingham, NCGC Acting Senior Health Economist, who discussed the baseline natural history transition probabilities of the Health Economic Model with the GDG. The Chair thanked SB for her presentation.
8. GS and RL then led discussion with the GDG on the research protocol for 1 clinical question. The following protocol was agreed and signed off by the GDG: in pregnant/lactating women with chronic hepatitis b, what is the clinical and cost effectiveness of adding anti-viral therapy of the mother to standard immunisation of the infant to reduce risk of vertical transmission from mother to infant?
9. There was no other business to discuss. The Chair closed the meeting and thanked everyone for attending.

Notes

Date, time and venue of the next meeting

10. Tuesday 19th June 2012, 10:30-16:30, NCGC Boardroom, 180 Great Portland Street, London, W1W 5QZ.